It remains to assess the efficacy of inhibition of DNAM-1 in vivo in other autoimmune diseases, in which CD226 was identified as a susceptibility genetic factor, such as type 1 diabetes and systemic lupus erythematosus [11,13,36]. Here, CD226 is linked to autoimmune disease.